Prognostic Value of Computed Tomography Radiomics Features in Patients with Gastric Cancer Following Curative Resection

Overview

Journal Eur Radiol

Specialty Radiology

Date 2018 Dec 7

PMID 30519931

Citations 34

Authors

Wuchao Li

Liwen Zhang

Chong Tian

Hui Song

Mengjie Fang

Chaoen Hu

Yali Zang

Ying Cao

Shiyuan Dai

Fang Wang

Di Dong

Rongpin Wang

Jie Tian

Affiliations

Soon will be listed here.

Abstract

Objectives: The present study aimed to investigate the clinical prognostic significance of radiomics signature (R-signature) in patients with gastric cancer who had undergone radical resection.

Methods: A total of 181 patients with gastric cancer who had undergone radical resection were enrolled in this retrospective study. The association between the R-signature and overall survival (OS) was assessed in the primary cohort and verified in the validation cohort. Furthermore, the performance of a radiomics nomogram integrating the R-signature and significant clinicopathological risk factors was evaluated.

Results: The R-signature, which consisted of six imaging features, stratified patients with gastric cancer who had undergone radical resection into two prognostic risk groups in both cohorts. The radiomics nomogram incorporating R-signature and significant clinicopathological risk factors (T stage, N stage, and differentiation) exhibited significant prognostic superiority over clinical nomogram and R-signature alone (Harrell concordance index, 0.82 vs 0.71 and 0.82 vs 0.74, respectively, p < 0.001 in both analyses). All calibration curves showed remarkable consistency between predicted and actual survival, and decision curve analysis verified the usefulness of the radiomics nomogram for clinical practice.

Conclusions: The R-signature could be used to stratify patients with gastric cancer following radical resection into high- and low-risk groups. Furthermore, the radiomics nomogram provided better predictive accuracy than other predictive models and might aid clinicians with therapeutic decision-making and patient counseling.

Key Points: • Radiomics can stratify the gastric cancer patients following radical resection into high- and low-risk groups. • Radiomics can improve the prognostic value of TNM staging system. • Radiomics may facilitate personalized treatment of gastric cancer patients.

Citing Articles

Prediction of lymphovascular invasion of gastric cancer based on contrast-enhanced computed tomography radiomics.

Zhen S, Wei Y, Song R, Liu X, Li P, Kong X Front Oncol. 2024; 14:1389278.

PMID: 39301548 PMC: 11410566. DOI: 10.3389/fonc.2024.1389278.

The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review.

Zhang S, Mu W, Dong D, Wei J, Fang M, Shao L Health Data Sci. 2024; 3:0005.

PMID: 38487199 PMC: 10877701. DOI: 10.34133/hds.0005.

Correlation Between Cognitive Impairment and Lenticulostriate Arteries: A Clinical and Radiomics Analysis.

Zhou L, Wu H, Zhou H J Imaging Inform Med. 2024; 37(4):1261-1272.

PMID: 38429561 PMC: 11300411. DOI: 10.1007/s10278-024-01060-7.

MRI-based automatic identification and segmentation of extrahepatic cholangiocarcinoma using deep learning network.

Yang C, Zhou Q, Li M, Xu L, Zeng Y, Liu J BMC Cancer. 2023; 23(1):1089.

PMID: 37950207 PMC: 10636947. DOI: 10.1186/s12885-023-11575-x.

Artificial intelligence applications in computed tomography in gastric cancer: a narrative review.

Ma T, Wang H, Ye Z Transl Cancer Res. 2023; 12(9):2379-2392.

PMID: 37859746 PMC: 10583011. DOI: 10.21037/tcr-23-201.

References

Weir J . Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res. 2005; 19(1):231-40. DOI: 10.1519/15184.1. View

Rutman A, Kuo M . Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009; 70(2):232-41. DOI: 10.1016/j.ejrad.2009.01.050. View

Hernan M . The hazards of hazard ratios. Epidemiology. 2009; 21(1):13-5. PMC: 3653612. DOI: 10.1097/EDE.0b013e3181c1ea43. View

Fridman W, Mlecnik B, Bindea G, Pages F, Galon J . Immunosurveillance in human non-viral cancers. Curr Opin Immunol. 2011; 23(2):272-8. DOI: 10.1016/j.coi.2010.12.011. View

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

Nishida T . Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet. 2012; 379(9813):291-2. DOI: 10.1016/S0140-6736(11)61928-4. View

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P . Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4):441-6. PMC: 4533986. DOI: 10.1016/j.ejca.2011.11.036. View

Kumar V, Gu Y, Basu S, Berglund A, Eschrich S, Schabath M . Radiomics: the process and the challenges. Magn Reson Imaging. 2012; 30(9):1234-48. PMC: 3563280. DOI: 10.1016/j.mri.2012.06.010. View

Komori M, Asayama Y, Fujita N, Hiraka K, Tsurumaru D, Kakeji Y . Extent of arterial tumor enhancement measured with preoperative MDCT gastrography is a prognostic factor in advanced gastric cancer after curative resection. AJR Am J Roentgenol. 2013; 201(2):W253-61. DOI: 10.2214/AJR.12.9206. View

10.

Zhang J, Fujimoto J, Zhang J, Wedge D, Song X, Zhang J . Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256-9. PMC: 4354858. DOI: 10.1126/science.1256930. View

11.

Kim Y . Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer?. Ann Surg Treat Res. 2014; 87(4):180-4. PMC: 4196431. DOI: 10.4174/astr.2014.87.4.180. View

12.

Tegels J, de Maat M, Hulsewe K, Hoofwijk A, Stoot J . Improving the outcomes in gastric cancer surgery. World J Gastroenterol. 2014; 20(38):13692-704. PMC: 4194553. DOI: 10.3748/wjg.v20.i38.13692. View

13.

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

14.

Morris L, Riaz N, Desrichard A, Senbabaoglu Y, Hakimi A, Makarov V . Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016; 7(9):10051-63. PMC: 4891103. DOI: 10.18632/oncotarget.7067. View

15.

Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H . Gastric cancer. Lancet. 2016; 388(10060):2654-2664. DOI: 10.1016/S0140-6736(16)30354-3. View

16.

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

17.

Giganti F, Antunes S, Salerno A, Ambrosi A, Marra P, Nicoletti R . Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. Eur Radiol. 2016; 27(5):1831-1839. DOI: 10.1007/s00330-016-4540-y. View

18.

Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M . Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer. 2016; 20(3):448-456. DOI: 10.1007/s10120-016-0637-x. View

19.

Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton J, Snyder A . Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol. 2016; 72(1):3-10. PMC: 5503113. DOI: 10.1016/j.crad.2016.09.013. View

20.

Cao Y, Liu H, Zhang H, Lin C, Li R, Wu S . CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. Oncotarget. 2016; 8(12):20328-20339. PMC: 5386765. DOI: 10.18632/oncotarget.12815. View